The human gut microbiota (HGM) are closely associated with health, development and 34 disease. The thick intestinal mucus layer, especially in the colon, is the key barrier between 35 the contents of the lumen and the epithelial cells, providing protection against infiltration by 36 the microbiota as well potential pathogens. The upper layer of the colonic mucus is a niche for 37 a subset of the microbiota which utilise the mucin glycoproteins as a nutrient source and mucin 38 grazing by the microbiota appears to play a key role in maintaining barrier function as well as 39 community stability. Despite the importance of mucin breakdown for gut health, the 40 mechanisms by which gut bacteria access this complex glycoprotein are not well understood. 41
Introduction 55
The human gastrointestinal (GI) tract is home to a large and complex community of microbes 56 known as the gut microbiota, which in the large intestine there is an estimated between 100-57 1000 trillion bacteria 1 . The mucous layer of the GI tract protects the underlying epithelia from 58 the huge microbial load of mutualists, environmental insults and enteric pathogens. 59
The GI mucus layer is predominantly composed of gel-forming mucins, which are complex 60 glycoproteins secreted by the epithelial cells 2 . Different mucins are expressed in different 61 mucosal surfaces throughout the body and a complete mucin glycoprotein is at least 50 % O-62 glycan by mass 3 . In the colon, MUC2 is the most abundant gel-forming mucin and is composed 63 of ~80 % glycan 1 . While the number of different monosaccharides making up mucin are 64 relatively limited, the order in which they can be assembled is hugely variable. This huge 65 heterogeneity between individual O-glycan chains and very complex macromolecules. It is this 66 glycan complexity that provides mucin's resistance to microbial degradation and contributes 67 to the mucus layers' protective role 4 . Notably, however, some prominent bacterial members 68 of the microbiota, including certain Bacteroidetes spp. and Akkermanisa muciniphila 5 , have 69 developed the capacity to graze on mucins 6-9 . This trait is thought to be critical to initial 70 colonisation by the microbiota in a new-born and therefore to the development of a healthy 71 adult microbiota 10 . Mucin grazing also enables survival during the absence of diet-derived 72 glycans 11 and non-mucin degrading species have been shown to be cross-fed by mucin 73 degraders, contributing to the long-term survival and stability of the microbiota 12,13 . By contrast, 74 aberrant or excess degradation of the mucosal layer by the normal microbiota has recently 75 been linked to enhanced pathogen susceptibility, inflammatory bowel disease and even 76 colorectal cancer 14, 11 . Despite the importance to gut health of mucin breakdown by the 77 microbiota, little is known about the molecular details of this process. Current models of mucin 78 degradation propose extracellular sequential trimming of terminal sugars from the O-glycan 79 side chains by exo-acting glycosidases to eventually expose the peptide backbone for 80 proteolysis 15 . However, this extracellular 'exo-trimming' model is based only on the activity of 81 currently characterised mucin active enzymes and notably is in direct contrast with the Gram-82 negative Bacteroidetes Sus-like paradigm for glycan breakdown, which requires a surface 83 endo-acting glycanase to cleave the substrate (polysaccharide or glycoconjugate) into smaller 84 oligosaccharides for uptake by the SusC/D OM complex [16] [17] [18] . Here we describe the discovery 85 and biochemical and structural characterisation of enzymes expressed by mucin degrading 86 members of the gut microbiota that are able to specifically cleave the O-glycan chains of a 87 range of different animal and human mucins in an endo-like manner. Many of these endo-O-88 glycanases are surface located and thus support a model where the initial step of mucin 89 degradation by gut bacteria is the extracellular removal of oligosaccharide chains from the fits the Sus paradigm and significantly enhances our understating of the mechanism of mucin 92 breakdown by the microbiota. Furthermore, the activity displayed by these enzymes suggest 93 they could be exploited as tools to explore changes that occur in mucin glycosylation in 94 intestinal disorders such as IBD and colon cancer.
Results 96

Identification of GH16 enzymes expressed during growth on mucin 97
Inspection of previously published transcriptomic and proteomic data from four Gram-98 negative prominent mucin degrading HGM species (B. thetaiotaomicron, B. fragilis, B. 99 caccae and A. mucinphila) identified genes and proteins which are likely involved in mucin 100 breakdown 8, 11, [19] [20] [21] [22] . These included many exo-acting enzymes from CAZy families 101 (carbohydrate active enzymes; CAZymes) previously identified as involved degradation of O-102 glycans, and in the case of Bacteroides spp., SusCD glycan import apparatus and putative 103 surface glycan binding proteins (pSGBPs; Supplementary Fig. 1-3) . Surprisingly, some of 104 the most upregulated CAZymes in all species analysed were from glycoside hydrolase family 105 16 (GH16). This is unexpected as GH16 enzymes are to date almost exclusively endo-acting 106
and have been predominantly characterised as targeting a variety of marine or terrestrial 107 plant polysaccharides, specifically β1,3 or 1,4 glycosidic bonds of glucans and galactans 108 ( Supplementary Fig 4) . More specifically, these enzymes are a part of subfamily 3 of this 109 family, which is a large and sequence-diverse subfamily characterised solely as β1,3/4-110 glucosidases found in Metazoa, Fungi, Archaea and Bacteria 23 . In total nine GH16 enzymes 111
were identified from the four species analysed ( Supplementary Fig. 1-3 
and Supplementary 112
Table 1). Sequence comparison of these enzymes with GH16 family members from other 113
Bacteroides spp. indicates that there may be similar enzymes present in species other than 114 the ones characterised in this report ( Supplementary Fig. 5 ). Furthermore, five of them are 115 predicted lipoproteins and therefore likely cell surface associated ( Supplementary Table 2 ). 116
For details on the genomic context of these genes and phylogenetic analysis see 
The GH16 enzymes are endo-acting mucinases 120
To explore the activity of the O-glycan-upregulated GH16 enzymes, the recombinant forms 121 of the enzymes were screened against mucin from porcine small intestinal (SI) mucin and 122 porcine stomach mucins (PGM type II and III; Supplementary Fig. 8 ). Initial analysis by TLC 123 suggested that all nine enzymes were active against both SI and gastric mucins and 124 released a range of products that are larger than monosaccharides from these glycoproteins, 125
indicating hydrolysis occurred at β-galactose (α-galactose only occurs in mucins as a 133
terminal sugar in blood group B structures) and the products also had a range of fucose and 134 sulfate decoration, revealing these can be accommodated by the GH16 enzymes. Overall 135 these data suggest the nine GH16 enzymes are all endo-acting β-galactosidases that are 136 active on the O-glycan side chains of mucin. Notably, sialic acid (SA) was never observed as 137 a decoration on any products released by the enzymes, even though SA is present on mucin 138 glycans. These data suggest this terminal sugar decoration cannot be accommodated by the 139 GH16 enzymes and, as a result, the broad acting sialidase BT0455 GH33 was included in all 140 assays to maximise access of the GH16 enzymes to the mucin chains. 141
The O-glycan products from the nine GH16 family members from SI mucin varied somewhat, 142 but could be split into two main groups (Fig. 2a ). The first group comprised six of the 143 enzymes (BT2824 GH16 , BF4058 GH16 , BF4060 GH16 , Baccac_02680 GH16 , Baccac_03717 GH16 , 144 and Amuc_2108 GH16 ) whose products were mainly made up of glycans no more than four 145 sugars in length, although very small amounts of longer oligosaccharides could be detected. 146
The second group composed of Baccac_02679 GH16 , Amuc_0724 GH16 and Amuc_0875 GH16 147 produced a mix of short and longer chain glycans (up to 6 sugars long). Amuc_0875 GH16 148 consistently had lowest relative activity against all mucins. 149
To investigate the structures of the oligosaccharide released by the GH16 enzymes in more 150 detail, the products of BF4058 GH16 degradation of SI mucin were treated with a series of exo-151 acting glycosidases of known specificity ( Fig. 2b and Supplementary Figs. 9 and 10). With 152 the inclusion of a broad acting α-1,2 fucosidase 24 , there is a different proportion of 153 oligosaccharides, notably, glycans 7 and 10 disappear and an increase in a relative 154 abundance of glycans 5 and 6 complements this. A bigger array of larger oligosaccharides 155 are now also observed suggesting that the fucosidase is allowing the GH16 enzyme access 156 to more complex structures. Glycan 6 shifts in position and these two different resolving 157 times indicate different isomers -for instance this could simply mean a different linkage 158 between two sugars or could be a completely different re-ordering of the monosaccharides 159 within a glycan. The fucosylations that are still present on the glycans produced in the 160 presence of fucosidase are likely to either be inaccessible to this particular enzyme or have 161 either α-1,3 or 4 linkages which are also present in mucins. 162
Inclusion of further exo-glycosidases with the BF4058 GH16 , sialidase and fucosidase digests 163 reveal further insight into the oligosaccharide structures released by the GH16. The addition 164 of a β1,4-galactosidase (BT0461 GH2 ) 25 removes one of the glycan 5 peaks, indicating this 165 saccharide is capped with a β1,4-galactose, while both glycan 5 peaks disappear with the 166 addition of a β1,3/4-galactosidase (BF4061 GH35 ; see Supplementary discussion and 167 supplementary Fig. 10 ), indicating the other glycan 5 peak is capped with a β1,3-galactose. disaccharide, although the position of the sulfation in not known so it is unclear at which 170 position the enzyme can accommodate this modification ( Fig. 2b, glycan 3) . 171
Exo-acting enzymes specific to either the α-GalNAc and α-galactose found on blood group A 172 or B structures, respectively, were also included ( Supplementary Fig. 9 ). No difference in 173 glycans was observed when an α-galactosidase was added, but inclusion of an α-174
GalNAc'ase revealed several of the larger oligosaccharides could be further degraded, 175 indicating these glycans have a capping α-GalNAc ( Fig. 2b, glycans 9 , 11, 13 and 16). 176
Keratan sulfate is structurally similar to mucin O-glycans in having a repeating polyLacNAc 177 structure with 6S sulfation possible on both the galactose and GlcNAc, but less fucosylation 178 and sialylation than most mucins. The nine GH16 family members were active against egg 179 and bovine corneal keratan sulfate ( Supplementary Fig. 11 ) and the released products 180
indicate that a number of sulfate groups can be tolerated by the enzymes (Supplementary 181 discussion). 182
A range of defined oligosaccharides were used to further probe the specificity of the O-183 glycan active GH16 enzymes. TriLacNAc is hydrolysed by nine GH16 enzymes initially 184 produce two trisaccharides, one of which is hydrolysed further to produce GlcNAc and 185 GlcNAcβ1,3Gal. The identity of the products was confirmed using specific exo-acting 186 enzymes ( Supplementary Fig. 12 ). The data revealed that all nine are endo β1,4-187 galactosidases with a requirement for a β1,3-linked sugar at the -2 position (Supplementary 188 Fig. 12-15 ). Furthermore, the GH16 enzymes all displayed a preference for GlcNAc over Glc 189 at the +1 site, revealing a discrimination for O-glycans over milk oligosaccharides which are 190 built on a lactose core. Activity on these defined oligosaccharides showed that sulfation and 191 fucosylation are not required for activity. Blood group sugars in the -3' (fucose) and -4 192 (GalNAc or Gal) sub-sites are tolerated in most cases but reduce the rate of activity (See 193
Supplementary discussion and Supplementary Table 4). 194
The activity of the nine recombinant GH16 enzymes was also tested against 195 polysaccharides previously shown to be GH16 substrates ( Supplementary Fig. 16 ). No 196 activity could be detected for agarose, κ-carrageenan, porphyran, pectic galactan, 197 xyloglucan or chitin. However, Amuc_0724 GH16 displayed significant endo activity against 198 laminarin and weak activity against barley β-glucan and lichenan. BF4060 GH16 , 199 Baccac_02680 GH16 and Baccac_03717 GH16 also displayed some very weak activity against 200 laminarin. The possible structural rationale for the activity of Amuc_0724 GH16 against Glc 201 configured substrates is discussed in the light of structural information and in the 202 Supplementary Discussion. Other non-mucin host polysaccharides are also present in 203 significant amounts in mucosal surfaces, including chondroitin sulfate (CS), heparan sulfate these and no significant activity could be found, except for small amounts of product 206 released from HS and this is explored in the Supplementary Discussion. 207 208
Crystal structures of O-glycan active GH16 family members 209
to investigate the basis for O-glycan specificity, structures were obtained for four out of the 210 nine O-glycan active GH16 family members. The apo structures of Baccac__02680 GH16 , 211
Baccac__02680 GH16E143Q , BACCAC_03717 GH16 and Amuc0724 GH16 were obtained to 2.0, 2.1, 212 2.1 and 2.7 Å, respectively. Structures of BF4060 GH16 and Baccac_02680 GH16E143Q were also 213 obtained with the Galβ1,4GlcNAcβ1,3Gal product present in the negative subsites (despite 214 the latter enzyme being a catalytic mutant) to 3.3 and 2.0 Å ( All of the GH16 enzymes comprise a β-jellyroll fold, characteristic of the family, consisting of 218 two β-sheets composed of β-strands that form the core fold, which were superimposable 219 with other GH16 structures previously published. A cleft running along the concave surface 220 of the enzymes contains the active site and where the trisaccharide product was bound in 221 the cases of BF4060 GH16 and Baccac_02680 GH16E143Q (Fig. 3a ). While the location of the 222 substrate binding site is conserved in the GH16 family, the structures of these clefts vary 223 depending on substrate specificity ( Supplementary Fig. 18a ). Some form a tight tunnel for 224 linear undecorated glycans (e.g. the agarase from Zobellia galactanivorans 26 ), others are 225 much more open to accommodate decorations (e.g. the xyloglucanase from Tropaeolum 226 majus 27 ), while some GH16 enzymes have substrate binding clefts that are curved to 227 optimise binding to highly curved glycans such as laminarin 28 . There is also a single example 228 of a GH16 family member that has evolved a pocket-like active site to recognise a specific 229 disaccharide 29 ( Supplementary Fig. 18b ). Substrate specificity in the GH16 family appears to 230 be dictated by the relative size and positon of the loops and short α-helices extending from 231 the β-strands surrounding the substrate binding cleft. These extensions have been likened to 232 fingers that interact with substrate, therefore modulating specificity, and that nomenclature is 233 used herein 30 . For the O-glycanase GH16 enzymes, BF4060 GH16 and Baccac_02680 GH16E143Q 234 have four fingers and BACCAC_03717 GH16 and Amuc0724 GH16 have five out of six possible 235 fingers that have been observed previously in other GH16 structures. 236
Inspection of the Baccac_02680 GH16E143Q and BF4060 GH16 structures with product reveal most 237 of the interactions between enzyme and ligand are with the Gal at -1 and GlcNAc at -2. The -238 1 subsite in Baccac_02680 GH16E143Q is composed of a number of aromatics, which are also a 239 common feature of the GH16 structures available (Fig. 3b ). This enzyme possesses four 240 fingers (numbers 1, 3, 5 and 6) that extend towards the cleft, with fingers 1 and 3 241 sandwiching the negative subsites and fingers 5 and 6 sandwiching the positive subsites.
Finger 3 contains the sequence motif for GH16 subfamily 3, which consists of three 243 tryptophans interspaced by other residues 23 . BF4060 GH16 and Baccac_02680 GH16 are 79 % 244 identical and the structures of these two enzymes are almost identical. In contrast, 245 BACCAC_03717 GH16 and Amuc0724 GH16 both have a finger 2 (in addition to 1, 3, 5 and 6) 246 and this has more variable topology of the other fingers ( Fig. 3a) . For Amuc_0724 GH16 , finger 247 2 sits over the top of finger 1, but in the BACCAC_03717 GH16 structure it points away from 248 the cleft. This could reflect the flexibility of finger 2 in this enzyme and could potentially come 249 down over loop 1 in solution like in the Amuc_0724 GH16 structure or have another role in 250 BACCAC_03717 GH16 . The B-factor putty projections of these structures show finger 2 is 251 dynamic in the BACCAC_03717 GH16 structure ( Supplementary Fig. 17 There are a number of structural features of the mucin active GH16 family members that 265 indicate a tailoring towards O-glycans as substrates, which include the polyLacNAc chains 266 and also fucose and sulfate decoration. Firstly, in the -1 subsites of the structures from 267
Bacteroides spp., the closed space around the O4 hydroxyl explains why only Gal 268 configured sugars can be recognised as the equatorial O4 of glucose would not be 269 accommodated (Fig. 3c ). The structure of Amuc_0724 GH16 in this area is much more open 270 and is a likely explanation for this enzymes additional activity against laminarin 271 ( Supplementary Fig. 18 ). Furthermore, the open space at the O4 in Amuc_0724 GH16 is a 272 potential pocket for sulfation that the Bacteroides spp. enzymes would not be able to 273 accommodate (Supplementary Discussion). Phylogenetic analysis reveals the mucin active 274 GH16 enzymes are likely to have derived from β-glucanases rather than β-galactanases 275 ( Supplementary Fig. 6 ), but in the -1 subsite the selection is for galactose rather than 276 glucose, which shows specificity for O-glycan structures. For the GH16 family there is no 277 conserved way of selecting between glucose and galactose and specificity for galactans example the endo-β1,3-galactanases), so this is an example of convergent evolution and the 280 side activity seen in Amuc_0724 GH16 is linked to its evolutionary origin. 281
Secondly specificity for polyLacNAcs in O-glycans requires a β1,3 linkage between the -1 282 and -2 sugars and the structural features driving this specificity in the O-glycan active GH16 283 enzymes are identical to those in the GH16 enzymes specific for mixed linkage β-284
glucanases. An aromatic residue in the -2 subsite (also a part of the sequence motif from the 285 subfamily) acts as a hydrophobic platform for the GlcNAc at this position and is at 90° 286 relative to an aromatic residue carrying out the same function in the -1. This feature is 287 conserved amongst β-glucanases (not in GH16 enzymes with other activities, see 288
Supplementary Discussion) and is also required also for the degradation of O-glycans. 289
Thirdly, at the -2 subsite where the GlcNAc is accommodated, the N-acetyl group of the 290 sugar faces the solvent. Other non-mucinase GH16 enzymes with tighter clefts would not be 291 able to accommodate this structure. Also in terms of the -2 subsite, overlay of a porphyran 292 product (originally from a porphyranase GH16 structure 32 ) into the clefts of the mucinase 293 GH16 enzymes indicates that sulfation on the GlcNAc at C3 could be accommodated within 294 the cleft at the -2 subsite ( Supplementary Fig. 19f ). 295
Fourthly, substrate depletion assays support a preference for polyLacNAc chains in the 296 positive subsites (compared to milk oligosaccharides, Supplementary Fig. 13 ). Although the 297 product complexes reported here do not have sugars in the positive subsites, comparison 298 with previously published GH16-substrates complexes could be used to propose a structural 299 rationale for the preference of GlcNAc at the +1 in the mucin active enzymes ( Fig. 3d and 300
Supplementary Discussion). BF4060 GH16 has a significant preference for triLacNAc over milk 301 oligosaccharides and analysis of the +1 subsite shows a narrow slot where a GlcNAc would 302 insert with the N-acetyl pointing away from the cleft and S174 from Finger 5 would pincer the 303 N-acetyl against finger 6, thus generating specificity for GlcNAc over glucose. The other 304 structures for O-glycan active GH16 enzymes presented here are more accommodating of 305 milk oligosaccharides and have more open +1 subsites ( Fig. 3d and Supplementary  306 Discussion). 307
308
The O-glycan active GH16 enzymes target human mucins from health and diseased 309 samples 310
We examined the activity of these GH16 family members on human-derived O-glycans from 311 three different disease states (Fig. 4) . Tissues from two adults suffering from ulcerative 312 colitis (UC) were obtained and preterm tissue samples from infants with NEC were from 4 313 infants of gestations 26, 27, 28 and 35 weeks. The three most preterm had terminal ileal Ulcerative colitis (UC) is one form of IDB characterised by an erosion of the mucosal layer 14 . 317
This allows the bacteria to contact the epithelial layer and induce an inflammatory response. 318
Necrotising enterocolitis (NEC) is a condition developed by premature infants where a 319 section of bowel dies, likely linked to an underdeveloped mucosal surface and parts of the 320 innate immune system being not yet active 33 . A complete understanding of all the factors 321 driving these diseases has yet to be full determined. Finally, CRC is the second and fourth 322 deadliest type of cancer in western countries and globally, respectively, and is exacerbated 323 by a 'Western' lifestyle, so is likely to become an increasing problem 34, 35 . Alterations in the 324 synthesis, secretion and composition of O-glycans in the mucosal surface of the colon have 325 been linked to causation and exasperation of UC and CRC 1,36-41 . 326
Human O-glycan samples were incubated with Amuc_0724 GH16 and sialidase BT0455 GH33 , 327 labelled with procainamide and analysed using the same methods as described above. 328
Profiles of GH16 O-glycan products could be produced from all the samples. This work 329 demonstrates that the O-glycan active GH16 family members provide another avenue for 330 researchers to analyse O-glycans in different disease states.
Discussion 332
Mucin turnover by the microbiota appears to play a key role in maintaining the normal barrier 333 function of the intestinal mucus layer 11 . Despite the importance of this process, our 334 understanding of the mechanism of mucin breakdown by the microbiota is fragmentary at best. 335
The current model, which is based mainly on the biochemical characterisation of individual 336 enzymes, proposes exo-acting glycosidases trim terminal sugars from the oligosaccharides 337 until the peptide backbone is exposed and can be cleaved by peptidases 15, 42 here, at least one of the GH16 endo-mucinases was a lipoprotein and therefore most likely 351 localised to the cell surface (see Supplementary Table 2 ). These data support a model in 352 which the endo-mucinases are cleaving oligosaccharide chains from intact mucin at the cell 353 surface and are therefore likely one of the initial steps in mucin breakdown by these bacteria. 354
The oligosaccharide products are then imported via the outer membrane SusC/D apparatus 355 and further degraded in the periplasm by a range of exo-acting enzymes, some of which we 356 also characterise here (e.g. α-fucosidases, β-galactosidases, β-hexosaminidases), but also in 357 some cases by periplasmic GH16 endo-mucinases (e.g. BF4060 GH16 , BACCAC_02680 GH16 ). 358
The presence of endo-acting enzymes in the periplasm has been described previously for 359 other glycan breakdown pathways 16 and may increase the efficiency of exo-cleavage by 360 rapidly generating substrates (i.e. chain ends) for the exo-acting enzymes. 361
While this model applies to Bacteroides spp, it is currently unknown how Akkermansia cells 362 access complex glycans, as while they are also Gram negative, there is no evidence of 363 SusC/D genes in the Verrucomicrobium phyla 6 . However, there is direct experimental 364 evidence that at least one of the GH16 mucinases expressed by A. muciniphila (Amuc_2108) 365 is localised to the outer membrane during growth on mucin, supporting a similar role to the that these enzymes are likely periplasmic, similar to those observed in Bacteroides spp. and 369 supporting exo-degradation of the surface GH16 released oligosaccharides in the periplasm 370 of Akkermasia. 371
Although targeting of polyLacNAc structures by the GH16 enzymes is likely an initial step in 372 mucin breakdown, further processing of the remaining mucin would be required. The 373 polyLacNAc side chains are attached directly to different core glycan structures, which are in 374 turn linked to the peptide backbone. One possibility for processing the remaining glycopeptide 375 is that extracellular or surface exo-acting glycosidases remove these core structures, prior to 376 peptidase action on the naked backbone, or that proteases are able to act on the core 377 glycosylated backbone to remove glycopeptides for uptake and further processing. This latter 378 model is supported by recent the recent discovery of a class of glyco-peptidases expressed 379 by gut microbes, including B. thetaiotaomicron, that specifically target O-glycosylated 380 mucins 43, 44 . 381
While much of the O-glycan that colonic microbiota will be exposed to will be from MUC2 45 , 382
as the major mucin expressed in the distal intestine, it is worth noting that these bacteria will 383 also come into contact with significant amounts of MUC5AC, MUC5B and MUC6 mucins that 384 have moved down the digestive tract from the saliva, oesophagus and stomach where they 385 originated. In addition to gel-forming mucins, gut microbes will be exposed to membrane-386 associated mucins that are a part of the apical surface glycocalyx of epithelial cells, especially 387 when dead cells are sloughed off the epithelium throughout the GI tract and these include 388 MUC3, MUC12 and MUC17 46,47 . Furthermore, greater than 80 % of secreted proteins are O-389 glycosylated and the gut microbiota will come into contact with these from both host and 390 dietary sources 48 . The PGM and SI used in this study indicate theses microbes can access 391 the different types of O-glycans moving through the GI tract. 392
Overall, the findings reported here contribute significantly towards the understanding about 393 the associations between the host and prominent members of the human gut microbiota. 394 Significantly, we were also able to use these enzymes to produce glycan fragments from with the possibility of extending the applications to other mucosal surfaces.
Materials and Methods 400
Sources of glycans and glycoproteins TriLacNAc was purchased from Elicityl and the rest 401 of the defined oligosaccharides were from Carbosynth. PGM II and III (Sigma) was produced 402 by dissolving in DI water at 50 mg/ml and the precipitate removed by centrifugation before 403 assays were carried out (leaving 35-40 mg/ml). Porcine small intestinal mucin was prepared 404 as previously described with the only modification being a double CsCl gradient without 405
Sepharose separation or SDS Page in between 49 . Keratan was prepared as described 406 previously 50 . 407 408
Bacterial strains 409
The Bacteroides strains used were: B. thetaiotaomicron VPI-5482 
Cloning, expression and purification of recombinant proteins 415
This was carried out as described in 25 . Data sets were integrated with XDS 51 or DIALS 52 or XIA2 53 and scaled with Aimless 54 . Initial 429 phases were obtained for Amuc_0724 GH16 For defined oligosaccharides and other polysaccharides, 3 μl of an assay containing 1 mM 458 substrate was spotted on to silica plates. For assays against mucin, this was increased to 9 459 μl. The plates were resolved in running buffer containing butanol/acetic acid/water (2:1:1) 460 and stained using a diphenylamine-aniline-phosphoric acid stain 65 . 461 462
Colorectal cancer cell line growth 463
Human CRC cell lines were obtained from the Department of Surgery of the Leiden 464 University Medical Center (LUMC), Leiden, The Netherlands. The cell lines cultured at the 465 LUMC were kept in Hepes-buffered RPMI 1640 culture medium containing L-glutamine and 466 supplemented with penicillin (5000 IU per mL), streptomycin (5 mg ml -1 ), and 10% (v/v) fetal 467 calf serum (FCS). Cells were incubated at 37˚C with 5% CO2 in humidified air. The cells 468 were harvested after reaching approximately 80% of confluence. To detach the cells from 469 the culture flask a trypsin/EDTA solution in 1X PBS was used. Enzyme activity was stopped 470 using the medium in a ratio 2:5 (trypsin:medium v/v). The cells were counted using TC20 mL of 1x PBS and pelleted by centrifuging 3 min at 1500 x g. Finally, the supernatant was 474 removed, and the cell pellets were stored at -20˚C. 2 million cells were used per reaction. 
PAD) 491
To analyse the substrate depletion assays, they were separated using a CARBOPAC PA-492 100 anion exchange column with a CARBOPAC PA-100 guard. Flow was 1 ml min -1 and 493 elution conditions were 0-10 min, 100 mM NaOH; 10-35 min 100 mM NaOH with a 0-166 494 mM sodium acetate gradient. 495 496
Procainamide labelling 497
Reducing ends of GH16 products were labelled by reductive amination using a procainamide 498 labelling kit containing sodium cyanoborohydride as reductant (Ludger). Before and after 499 labelling the O-glycan samples were cleaned up using PBM plates and S-cartridges, 500 respectively (Ludger). for mucin and keratan samples, respectively. The Amazon speed was operated in the 512 positive sensitivity mode using the following settings: source temperature, 180 °C; gas flow. 513 41 min -1 ; capillary voltage, 4,500 V; ICC target, 200,000; maximum accumulation time, 50.00 514 ms; rolling average, 2; number of precursor ions selected, 3; scan mode, enhanced 515 resolution; mass range scanned, 400 to 1,700. 516 517
Analysis of mass spectrometry data 518
Mass spectrometry of procainamide-labelled glycans was analysed using Bruker Compass 519
Data Analysis Software and GlycoWorkbench 66 . Glycan compositions were elucidated on the 520 basis of MS 2 fragmentation and previously published data. 521 522
Bioinformatics 523
Putative signal sequences were identified using SignalP 5.0 67 . Sequence identities were 524 determined using Clustal Omega using full sequences 68 . The IMG database was used to 525 analyse synteny between different species 69 . The CAZy database (www.cazy.org ) was used 526 as the main reference for CAZymes 70 . Alignments and phylogenetic trees were completed in 527 SeaView 71 . To determine the boundaries between different modules in a protein Pfam 72 and 528 SMART 73,74 were used. 529
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Diamond Light Source (Oxfordshire, UK) for beamtime (proposal mx18598) and staff of 534 beamline I03, I04-1 and I24. We are grateful to Newcastle Biobank and NIHR Newcastle 535 were labelled with procainamide at the reducing end and analysed by LC-FLD-ESI-MS. From top to bottom the chromatograms correspond to control, BT2824 GH16 , BF4058 GH16 , BF4060 GH16 , Baccac_02679 GH16 , Baccac_02680 GH16 , Baccac_03717 GH16 , Amuc_0724 GH16 , Amuc_0875 GH16 and Amuc_2108 GH16 , respectively. The locus tags on the figure has been shortened for clarity and labels are shown above each chromatogram. All samples were pre-treated with a broad-acting sialidase (BT0455 GH33 ) to maximise access of the GH16 enzymes to the mucin chains. b, BF4058 GH16 products were treated with a series of exo-acting enzymes to provide further insight into the products released. Labels are shown below each chromatogram. Red asterisks highlight peaks that disappear with the addition of an exo-enzyme. See Supplementary Figs. 9, 10 (Galβ1,4GlcNAcβ1,3Gal ). The residues interacting directly with sugar are shown as sticks. The aromatic residues shared with β-glucanase GH16 family members that drive specificity for a β1,3 between the -1 and -2 sugars are shown (insert numbers here; See Supplementary Fig. 17 for active sites of Baccac_03717 GH16 , and Amuc_0724 GH16 ). c, A surface representation of the regions surrounding the -1 subsite showing the selection for the axial O4 of Gal in the three Bacteroides enzymes, while Amuc_0724 has a more open 'tunnel' like space that appears to also allow accommodation of the equatorial O4 of Glc. The product from Baccac_02680 GH16E143Q was overlaid in the Baccac_03717 GH16 , and Amuc_0724 GH16 structures. Colours represent the different 'fingers'. d, A view of the predicted positive subsites of BF4060 GH16 and Baccac_03717 GH16 overlaid with the glucose from the +1 subsite of a laminarinase from Phaenerochaete chrysosporium. The positive subsites are much more closed for BF4060 GH16 and Baccac_02680 GH16E143Q compared to Baccac_03717 GH16 , and Amuc_0724 GH16 ( Supplementary Fig. 17 ). e, An overview of the monosaccharides occupying the different subsites in GH16 family members with different activities. Linkages also shown. Products of mucin digestion were labelled with procainamide at the reducing end and analysed by LC-FLD-ESI-MS. All samples were pre-treated with the broad acting sialidase BT0455 GH33 a, Products of GH16 digestion of mucin samples from two patients with ulcerative colitis. Patient 1 had a laproascopic panproctocolectomy and all removed colon was inflamed. Sample 1A is uninflamed ileum and 1B from inflamed colon. Patient 2 had a laprascopic ileocaecal resection. Sample 2A inflamed ileum (bowel terminal ileum), 2B from uninflamed ileum (near small bowel staple line) and 2C from uninflamed colon (ascending). b, Mucin from neonates with necrotising enterocolitis. Each sample is a different patient c, Mucin from colorectal cancer cell lines. Small amounts of Neu5Gc are seen in some of the ulcerative colitis samples (e.g. 1A)
suggesting either the presence of contaminating dietary animal O-glycans remaining in the mucus layer or that this xenobiotic sugar has been incorporated into human mucins from dietary sources.
